Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accumulated Expenses (2019 - 2025)

Bioadaptives' Accumulated Expenses history spans 7 years, with the latest figure at $215973.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $215973.0 for Q4 2025, up 25.93% from a year ago — trailing twelve months through Dec 2025 was $215973.0 (up 25.93% YoY), and the annual figure for FY2025 was $215973.0, up 25.93%.
  • Accumulated Expenses for Q4 2025 was $215973.0 at Bioadaptives, up from $203997.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $215973.0 in Q4 2025 to a low of $1003.0 in Q1 2022.
  • The 5-year median for Accumulated Expenses is $126294.0 (2023), against an average of $96678.4.
  • The sharpest move saw Accumulated Expenses tumbled 90.85% in 2022, then skyrocketed 14223.16% in 2024.
  • Year by year, Accumulated Expenses stood at $6200.0 in 2021, then soared by 1527.73% to $100919.0 in 2022, then soared by 36.7% to $137955.0 in 2023, then grew by 24.32% to $171507.0 in 2024, then rose by 25.93% to $215973.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $215973.0, $203997.0, and $190167.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.